Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.77 |
| ▸ | HTR2A | P28223 | 7/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429472 | 0.87 | MCHR1 (0.74) | MCHR1HTR2ACHRM1MAPTNPC1 | |
| SCHEMBL4591118 | 0.83 | MCHR1 (0.69) | MCHR1HTR2ACHRM1MAPTNPC1 | |
| SCHEMBL4591182 | 0.83 | MCHR1 (0.69) | MCHR1HTR2ACHRM1MAPTNPC1 | |
| SCHEMBL4591650 | 0.83 | MCHR1 (0.69) | MCHR1HTR2ACHRM1MAPTNPC1 | |
| SCHEMBL4592187 | 0.82 | MCHR1 (1.00) | MCHR1HTR2ACHRM1 | |
| SCHEMBL4592220 | 0.79 | MCHR1 (0.55) | MCHR1HTR2ACHRM1MAPTNPC1 | |
| SCHEMBL4591565 | 0.79 | MCHR1 (0.80) | MCHR1HTR2ACHRM1 | |
| SCHEMBL14503852 | 0.78 | MCHR1 (0.81) | MCHR1HTR2ACHRM1 | |
| SCHEMBL5421737 | 0.77 | MCHR1 (0.61) | MCHR1HTR2ACHRM1MAPTNPC1 | |
| SCHEMBL5420311 | 0.74 | MCHR1 (0.61) | MCHR1HTR2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885HTR2A 66/4885CHRM1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.